BfArM - Federal Institute for Drugs and Medical Devices

Navigation and service

Search i

Search help

  • Enter one or more search terms in the search field. Upper and lower case are not relevant.
  • As soon as you have entered three letters in the search field, various search words will be suggested from which you can choose one.
  • If you are searching for a certain group of words, put these words in double quotes. The hits will then contain the words in the order you entered, e.g. "medicines for children".
  • Multiple search terms can also be combined with the Boolean operators AND and OR. When using the operator AND, the results contain the intersection of all search terms. When using the operator OR, the hits contain one of the search terms or only individual search terms. The result set is therefore significantly larger. Please note that these operators must be written in capital letters.
  • If you receive a (too) large number of hits as a result of your search, you can narrow it down by using filters. These filter options appear to the left of the search results and are subdivided into:

    • category (e.g. safety of medicinal products, medical devices, code systems)
    • format (e.g. download, risk information, DHPCs)
    • time interval (e.g. last 30 days, older than ...)
  • Selected filters can be removed individually or all at once ("Show all results").
  • By default, search results are sorted by relevance, but they can also be sorted chronologically ("Latest entries first" or "Oldest entries first").

Enter search term

818 results

Results per page: 10 20 30

Medicinal products containing ambroxol and bromhexine: recommendation of the Pharmacovigilance Risk Assessment Committee (PRAC) and the Co-ordination group (CMDh) within a European safety review concerning the risk of hypersensitivity reactions Date: 10. March 2015 Topics: Pharmakovigilanz Type: Risk Assessment Procedures

Active substance: ambroxol | bromhexine

The BfArM issues information on a recommendation by the PRAC and the resulting majority decision by the Co-ordination group for Mutual recognition and Decentralised procedures – human (CMDh) within a European safety review in accordance with …

Neulasta®: Possibility of counterfeits being on the market Date: 06. March 2015 Topics: Pharmakovigilanz Type: Risk information

Active substance: pegfilgrastim

The Federal Institute for Drugs and Medical Devices (Bundesinstitut für Arzneimittel und Medizinprodukte, BfArM) has received information via the "Land" authority ("Landesbehörde") of Bavaria and via the EU's Rapid Alert System (RAS) that …

Cialis®: Counterfeit medicinal products from Italy - Update Date: 24. February 2015 Topics: Pharmakovigilanz Type: Risk information

Active substance: tadalafil

The BfArM is reporting further information from the company Lilly as the marketing authorisation holder of the originator product.

Information on theft of the medicinal product Sildaristo® produced by Aristo Pharma GmbH in Berlin Date: 12. February 2015 Topics: Pharmakovigilanz Type: Risk information

Active substance: sildenafil

The State Office of Health and Social Affairs in Berlin ("Landesamt für Gesundheit und Soziales", LaGeSo) has informed the BfArM of the theft of the medicinal product Sildaristo®.

Polymyxin-based products (colistin, colistimethate sodium): realisation of the EU Commission's implementing decision Date: 30. January 2015 Topics: Pharmakovigilanz Type: Risk Assessment Procedures

Active substance: colistin | colistimethate sodium

Based on the review of the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), the European Commission decided on 16 December 2014 to update the product informations of medicinal products containing …

Medicinal products containing testosterone: review of possible cardiac risks Date: 22. January 2015 Topics: Pharmakovigilanz Type: Risk Assessment Procedures

Active substance: testosterone

The Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) has reviewed the risk of cardiovascular diseases, particularly heart attacks, under treatment with testosterone.

Medicinal products containing ponatinib (Iclusig®): risk of blood vessel blockage Date: 15. January 2015 Topics: Pharmakovigilanz Type: Risk Assessment Procedures

Active substance: Ponatinib

With the publication of the decision of the European Commission on 15 January 2015, the risk assessment procedure for Iclusig® was completed.

Medicinal products containing valproate and related substances: risk of anomalies in neonates Date: 13. January 2015 Topics: Pharmakovigilanz Type: Risk Assessment Procedures

Active substance: valproate

On 19 November 2014, the Co-ordination group for Mutual recognition and Decentralised procedures – human (CMDh) decided unanimously based on the recommendations of the European Medicines Agency’s (EMA) Pharmacovigilance Risk Assessment …

Medicinal products containing Estradiol for topical administration: realisation of the EU Commission's implementing decision Date: 09. January 2015 Topics: Pharmakovigilanz Type: Risk Assessment Procedures

Active substance: estradiol

In its notice of 9 January 2015, the Federal Institute for Drugs and Medical Devices (BfArM) has ruled the realisation of the corresponding implementing decision of the EU Commission C(2014)6030 of 19 August 2014

Dear Doctor Letter (Rote-Hand-Brief) on Rapiscan® (regadenoson): New information regarding the minimisation of the stroke risk and prolongation of Rapiscan-induced seizures after administration of aminophylline PDF, 194KB, File is accessible Date: 22. December 2014 Topics: Pharmakovigilanz Type: Direct Healthcare Professional Communication

Active substance: regadenoson

The company Rapidscan Pharma Solutions is circulating new safety information. Postponement of regadenoson administration should be considered in patients with uncontrolled hypertension.

Dear Doctor Letter (Rote-Hand-Brief) on SonoVue® (sulphur hexafluoride): Revised contraindications, warnings and precautions PDF, 589KB, File is accessible Date: 18. December 2014 Topics: Pharmakovigilanz Type: Direct Healthcare Professional Communication

Active substance: sulphur hexafluoride

The company Bracco Imaging Deutschland GmbH is circulating information on rare but severe arrhythmias, sometimes fatal, in patients with cardiovascular instability during stress echocardiography procedures with SonoVue® used in combination …

Dear Doctor Letter (Rote-Hand-Brief) on CellCept® (mycophenolate mofetil): New warnings with regard to the risk of hypogammaglobulinaemia and bronchiectasis PDF, 2MB, File is accessible Date: 17. December 2014 Topics: Pharmakovigilanz Type: Direct Healthcare Professional Communication

Active substance: mycophenolate mofetil

The company Roche Pharma AG is circulating new safety information regarding the risk of hypogammaglobulinaemia and bronchiectasis for all products that release mycophenolic acid as the active metabolite.

Dear Doctor Letter (Rote-Hand-Brief) on medicinal products containing valproate (and related substances): Risks for the unborn child in case of exposure during pregnancy Date: 12. December 2014 Topics: Pharmakovigilanz Type: Direct Healthcare Professional Communication

Active substance: valproat, related substances

Important new information and increased safety warnings with regard to medicinal products containing valproate and related substances (sodium valproate, valproic acid, valproate semisodium and valpromide).

Dear Doctor Letter (Rote-Hand-Brief) on Procoralan® (ivabradine): New contraindication and recommendations for minimisation of risks of cardiovascular events and severe bradycardias PDF, 1MB, File is accessible Date: 11. December 2014 Topics: Pharmakovigilanz Type: Direct Healthcare Professional Communication

Active substance: ivabradine

The company Servier Deutschland GmbH is circulating information that concomitant use of ivabradine with verapamil or diltiazem is now contraindicated.

Marketing authorisations based on studies conducted by GVK Biosciences in India: suspension of marketing authorisation Date: 09. December 2014 Topics: Pharmakovigilanz Type: Risk Assessment Procedures

Active substance: various

In a notice dated 8 December 2014, the Federal Institute for Drugs and Medical Devices (BfArM) has ruled the suspension of several marketing authorisations that were based on a clinical trial conducted by GVK Biosciences in India.

Dear Doctor Letter (Rote-Hand-Brief) on Tecfidera® (dimethyl fumarate): Suspected case of progressive multifocal leukoencephalopathy (PML) PDF, 195KB, File is accessible Date: 04. December 2014 Topics: Pharmakovigilanz Type: Direct Healthcare Professional Communication

Active substance: dimethyl fumarate

The company Biogen Idec GmbH is circulating information on a fatal case of progressive multifocal leukoencephalopathy (PML) in a patient with a severe and long-term lymphopenia treated with Tecfidera®.

Dear Doctor Letter (Rote-Hand-Brief) on medicinal products containing bromocriptine: Restrictions of indication regarding inhibition of lactation PDF, 1MB, File is accessible Date: 04. December 2014 Topics: Pharmakovigilanz Type: Direct Healthcare Professional Communication

Active substance: bromocriptine

The marketing authorisation holders of medicinal products containing bromocriptine are circulating information that bromocriptine should only be taken in strengths up to 2.5 mg per individual dose for prevention or inhibition of lactation …

Information on medicinal products affecting the renin-angiotensin system: Key elements for communication PDF, 42KB, File is accessible Date: 01. December 2014 Topics: Pharmakovigilanz Type: Direct Healthcare Professional Communication

Active substance: ACE-Hemmer, Angiotensin-II-Rezeptor-Antagonisten, Aliskiren

The Pharmacovigilance Risk Assessment Committee (PRAC) has adopted key elements regarding communication of the outcome of the safety review regarding medicinal products that affect the renin-angiotensin system.

Oral bromocriptine-containing medicines: indicated in the prevention or suppression of physiological lactation post-partum Date: 28. November 2014 Topics: Pharmakovigilanz Type: Risk Assessment Procedures

Active substance: bromocriptine

In its notice of 27 November 2014, the Federal Institute for Drugs and Medical Devices (BfArM) has ruled the realisation of the corresponding implementing decision of the EU Commission of 30 October 2014 regarding medicinal products containing …

Information Letter on Eligard® (leuprorelin acetate depot injection): Risk of lack of efficacy due to incorrect reconstitution and administration PDF, 521KB, File is accessible Date: 28. November 2014 Topics: Pharmakovigilanz Type: Direct Healthcare Professional Communication

Active substance: leuprorelin acetate

The company Astellas Pharma GmbH is circulating information on a possible lack of clinical efficacy that may occur if the product is reconstituted incorrectly.

Counterfeit medicinal products in Spain Date: 26. November 2014 Topics: Pharmakovigilanz Type: Risk information

Active substance:

On 18 November 2014, the Spanish licensing authority Agencia Española de Medicamentos y Productos Sanitarios (AEMPS--Agencia Española de Medicamentos y Productos Sanitarios) issued information on initial findings on illegally traded medicinal …

Dear Doctor Letter (Rote-Hand-Brief) on Fenistil® 1 mg/ml solution for injection (dimethindene maleate): Quality defects; recall of two batches PDF, 483KB, File is accessible Date: 25. November 2014 Topics: Pharmakovigilanz Type: Direct Healthcare Professional Communication

Active substance: dimethindene maleate

The company Novartis Consumer Health GmbH is sending out information on the recall of batches 11027154 and 11045012 of the medicinal product Fenistil® 1 mg/ml solution for injection as the vials of both batches partially exhibit leakage at the …

Medicinal products that affect the renin-angiotensin(-aldosterone) system (RAS/RAAS): realisation of the EU Commission's implementing decision Date: 13. November 2014 Topics: Pharmakovigilanz Type: Risk Assessment Procedures

Active substance: ACE-Hemmer | Angiotensin-II-Rezeptor-Antagonisten | Aliskiren

In its notice of 31 October 2014, the Federal Institute for Drugs and Medical Devices (BfArM) has ruled the realisation of the corresponding implementing decision (2014) 6371 of the EU Commission.

Information letter on medicinal products containing codeine as liquid dosage forms by UCB Pharma GmbH: Recall Date: 13. November 2014 Topics: Pharmakovigilanz Type: Direct Healthcare Professional Communication

Active substance: codein

The company UCB Pharma GmbH is circulating information on the recall of medicinal products containing codeine as liquid dosage forms.

Levonorgestrel- and ulipristal acetate-containing medicines for emergency contraception: influence of body weight/BMI on efficacy/bioavailability Date: 07. November 2014 Topics: Pharmakovigilanz Type: Risk Assessment Procedures

Active substance: levonorgestrel | ulipristal acetate

In its notice of 5 November 2014, the Federal Institute for Drugs and Medical Devices (BfArM) has ruled the realisation of the corresponding implementing decision C(2014)7147of the EU Commission.

Tecfidera® (dimethyl fumarate): First case of progressive multifocal leukoencephalopathy (PML) Date: 07. November 2014 Topics: Pharmakovigilanz Type: Risk information

Active substance: dimethyl fumarate

At the request of the BfArM, the Pharmacovigilance Risk Assessment Committee (PRAC) discussed a fatal case of progressive multifocal leukoencephalopathy (PML) which was reported in a patient treated with Tecfidera® (dimethyl fumarate) at its …

Information letter on Xofigo® (radium 223 dichloride): Temporary shortage of the medicinal product and special temporary preparation instructions. PDF, 75KB, File is accessible Date: 07. November 2014 Topics: Pharmakovigilanz Type: Direct Healthcare Professional Communication

Active substance: radium-223-dichlorid

The company Bayer Vital GmbH is circulating information on a worldwide temporary shortage of the medicinal product Xofigo® as recently produced batches did not pass routine quality checks prior to release.

Information Letter on Xofigo® (radium 223 dichloride): Temporary shortage of the medicinal product PDF, 2MB, File is accessible Date: 05. November 2014 Topics: Pharmakovigilanz Type: Direct Healthcare Professional Communication

Active substance: radium-223-dichlorid

The company Bayer Vital GmbH is circulating information on a worldwide temporary shortage of the medicinal product Xofigo® as recently produced batches did not pass routine quality checks prior to release.

Dear Doctor Letter (Rote-Hand-Brief) on Beofenac® (aceclofenac): New contraindications and warnings PDF, 1MB, File is accessible Date: 28. October 2014 Topics: Pharmakovigilanz Type: Direct Healthcare Professional Communication

Active substance: aceclofenac

The company Almirall Hermal GmbH is circulating information that treatment with aceclofenac - similar to that with diclofenac and selective COX-2 inhibitors - is associated with an increased risk of arterial thrombotic events.

Use of valproate (and related substances) during pregnancy: recommendation of the Pharmacovigilance Risk Assessment Committee (PRAC) within a European safety review Date: 10. October 2014 Topics: Pharmakovigilanz Type: Risk Assessment Procedures

Active substance: valproate

The BfArM issues information on the PRAC's recommendation within a European safety review according to Article 31 of Directive 2001/83/EC.